One mechanism that has been proposed for the suppressive role of miR-145-5p in PCa progression is the inhibition of the IGF-1/1R pathway, which is associated with bone metastasis and can activate growth factor receptors, such as c-MET, a target for many inhibitors now in clinical trials for mCRPC [50,51]. The gene discussed is MET; the disease is posterior cortical atrophy.